IRON Strengthens, MNMD Offers Reassurance to Investors, Could NKTR Experience an Early Christmas?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 19 2025
0mins
Should l Buy NKTR?
Source: NASDAQ.COM
Fidelity Investments Insight: Abigail Johnson emphasizes the importance of understanding investments, highlighting that successful investing is about knowing what you own and why.
Disc Medicine Inc. Update: The company submitted a New Drug Application for its drug Bitopertin to treat erythropoietic protoporphyria, receiving a priority voucher for expedited review, with stock reaching a 52-week high of $95.95.
Mind Medicine Inc. Developments: The company is preparing for pivotal data readouts in 2026 for its lead drug candidate, MM120, with stock hitting a 52-week high of $13.86.
Nektar Therapeutics Progress: The company reported significant results from its phase 2b trial for atopic dermatitis, with stock reaching a 52-week high of $63.92, and anticipates further data in early 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 69.150
Low
102.00
Averages
123.43
High
165.00
Current: 69.150
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Nektar Therapeutics in the Northern District of California on behalf of investors who purchased securities between February 26, 2025, and December 15, 2025, seeking damages for violations of federal securities laws.
- Trial Results Disappoint: On December 16, 2025, Nektar announced that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a 7.77% drop in stock price, equating to a loss of $4.14 per share, highlighting potential issues in the company's clinical trial processes.
- Allegations of Misrepresentation: The complaint alleges that Nektar executives made materially false and misleading statements during the class period, failing to disclose that trial enrollment did not adhere to applicable standards, which could significantly impact trial outcomes and investor confidence.
- Investor Action Deadline: Investors have until May 5, 2026, to apply to be appointed as Lead Plaintiff in the class action, underscoring concerns regarding corporate governance and transparency in Nektar's operations.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Allegation: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial results, while the company overstated the integrity of the trial, resulting in misleading public statements.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, emphasizing its specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
- Market Reaction Impact: As the market learned the truth about Nektar, investors suffered damages, highlighting significant failures in the company's disclosure practices, which could lead to stock price declines and affect future investor confidence.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: DJS Law Group alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, involving shareholders who purchased shares from February 26, 2025, to December 15, 2025, indicating significant legal risks for the company.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA study, likely negatively impacting trial results, suggesting that the company's public statements were false and misleading throughout the class period, which could undermine investor confidence.
- Investor Participation Opportunity: Shareholders who suffered losses are encouraged to contact DJS Law Group to participate in the lawsuit and potentially serve as lead plaintiffs, indicating that the company faces potential financial liability risks that could affect its stock performance.
- Legal Service Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, emphasizing its legal services for large hedge funds and alternative asset managers, showcasing its expertise and market influence in handling complex legal matters.
See More
Class Action Lawsuit Announced for Nektar Therapeutics
- Class Action Initiation: Rosen Law Firm announces a class action lawsuit against Nektar Therapeutics for securities purchasers between February 26, 2025, and December 15, 2025, indicating potential investor losses due to misleading statements.
- Compensation Structure: Investors joining the lawsuit may receive compensation without any out-of-pocket fees, highlighting the accessibility of legal services and the protection of investor rights.
- Allegations Details: The lawsuit claims that Nektar failed to adhere to applicable standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and potentially impacting the company's reputation and stock price negatively.
- Law Firm Credentials: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Nektar Therapeutics Faces Class Action Over Misleading Trial Results
- Lawsuit Background: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, alleging the company failed to disclose that enrollment in the REZOLVE-AA trial did not follow applicable standards.
- Trial Results Failure: On December 16, 2025, Nektar announced that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a stock price drop of $4.14, or 7.77%, to close at $49.16, indicating a significant loss of market confidence in its product prospects.
- False Statement Allegations: The complaint claims that Nektar overstated the overall integrity and prospects of the trial, leading to materially false and misleading public statements throughout the relevant period, which could have severe implications for investor trust.
- Shareholder Rights Protection: Robbins LLP offers contingency-based representation, allowing shareholders to participate in the lawsuit without upfront costs, aiming to help recover losses and improve corporate governance structures.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Lawsuit Background: A securities class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of all investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, highlighting significant investor concerns regarding the company's transparency.
- Allegations: The complaint alleges that the defendants failed to disclose that enrollment in the REZOLVE-AA trial did not adhere to applicable instructions and protocol standards, which could significantly impact the trial's results, thereby misleading investors about the company's prospects.
- Impact Assessment: The overall integrity and prospects of the REZOLVE-AA trial were overstated, leading to materially false and misleading public statements by the defendants at all relevant times, which could result in a decline in investor confidence and negatively affect the company's stock price.
- Investor Action: Investors are urged to contact Gainey McKenna & Egleston before the May 5, 2026, lead plaintiff motion deadline to express their rights and interests in the class action, emphasizing the importance of protecting their investments.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Nektar Therapeutics in the Northern District of California on behalf of investors who purchased securities between February 26, 2025, and December 15, 2025, seeking damages for violations of federal securities laws.
- Trial Results Disappoint: On December 16, 2025, Nektar announced that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a 7.77% drop in stock price, equating to a loss of $4.14 per share, highlighting potential issues in the company's clinical trial processes.
- Allegations of Misrepresentation: The complaint alleges that Nektar executives made materially false and misleading statements during the class period, failing to disclose that trial enrollment did not adhere to applicable standards, which could significantly impact trial outcomes and investor confidence.
- Investor Action Deadline: Investors have until May 5, 2026, to apply to be appointed as Lead Plaintiff in the class action, underscoring concerns regarding corporate governance and transparency in Nektar's operations.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Allegation: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial results, while the company overstated the integrity of the trial, resulting in misleading public statements.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, emphasizing its specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
- Market Reaction Impact: As the market learned the truth about Nektar, investors suffered damages, highlighting significant failures in the company's disclosure practices, which could lead to stock price declines and affect future investor confidence.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: DJS Law Group alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, involving shareholders who purchased shares from February 26, 2025, to December 15, 2025, indicating significant legal risks for the company.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA study, likely negatively impacting trial results, suggesting that the company's public statements were false and misleading throughout the class period, which could undermine investor confidence.
- Investor Participation Opportunity: Shareholders who suffered losses are encouraged to contact DJS Law Group to participate in the lawsuit and potentially serve as lead plaintiffs, indicating that the company faces potential financial liability risks that could affect its stock performance.
- Legal Service Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, emphasizing its legal services for large hedge funds and alternative asset managers, showcasing its expertise and market influence in handling complex legal matters.
See More
Class Action Lawsuit Announced for Nektar Therapeutics
- Class Action Initiation: Rosen Law Firm announces a class action lawsuit against Nektar Therapeutics for securities purchasers between February 26, 2025, and December 15, 2025, indicating potential investor losses due to misleading statements.
- Compensation Structure: Investors joining the lawsuit may receive compensation without any out-of-pocket fees, highlighting the accessibility of legal services and the protection of investor rights.
- Allegations Details: The lawsuit claims that Nektar failed to adhere to applicable standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and potentially impacting the company's reputation and stock price negatively.
- Law Firm Credentials: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Nektar Therapeutics Faces Class Action Over Misleading Trial Results
- Lawsuit Background: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, alleging the company failed to disclose that enrollment in the REZOLVE-AA trial did not follow applicable standards.
- Trial Results Failure: On December 16, 2025, Nektar announced that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a stock price drop of $4.14, or 7.77%, to close at $49.16, indicating a significant loss of market confidence in its product prospects.
- False Statement Allegations: The complaint claims that Nektar overstated the overall integrity and prospects of the trial, leading to materially false and misleading public statements throughout the relevant period, which could have severe implications for investor trust.
- Shareholder Rights Protection: Robbins LLP offers contingency-based representation, allowing shareholders to participate in the lawsuit without upfront costs, aiming to help recover losses and improve corporate governance structures.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Lawsuit Background: A securities class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of all investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, highlighting significant investor concerns regarding the company's transparency.
- Allegations: The complaint alleges that the defendants failed to disclose that enrollment in the REZOLVE-AA trial did not adhere to applicable instructions and protocol standards, which could significantly impact the trial's results, thereby misleading investors about the company's prospects.
- Impact Assessment: The overall integrity and prospects of the REZOLVE-AA trial were overstated, leading to materially false and misleading public statements by the defendants at all relevant times, which could result in a decline in investor confidence and negatively affect the company's stock price.
- Investor Action: Investors are urged to contact Gainey McKenna & Egleston before the May 5, 2026, lead plaintiff motion deadline to express their rights and interests in the class action, emphasizing the importance of protecting their investments.
See More
